During the first four years of this funding period, The Ohio State University Comprehensive Cancer Center (OSUCCC) has experienced growth and expansion of its Programs, primarily related to the opening of the Arthur G. James Cancer Hospital and Research Institute (CHRI) in July, 1990. The OSUCCC organization reflects importance. The OSUCCC Director also serves as the CHRI Director and oversees the CHRI administration. Of the 68 OSU interdisciplinary academic Centers, it is the only one whose director has a direct reporting relationship to the President and Board of Trustees of the University. The OSUCCC organizational model links all of the OSUCCC research Programs to the respective cancer disease sites. This reflects the OSUCCC leadership's recognition that one of its primary responsibilities involves facilitating, expanding, and expediting translational research activities. This application will describe the past accomplishments and future plans of the thirteen OSUCCC Programs which are served by thirteen OSUCCC shared services. It will also describe future plans for the next funding period which include the development of a major new Program in human cancer genetics. The request for support described in this application is a strong attempt by OSUCCC leadership to recognize its responsibility to the national community of NCI approved cancer Centers during this difficult time of budgetary constraints for support of NCI Centers. Accordingly, the budget request in this competitive renewal application for Year 21 represents a reduction in the prior year CCSG support. The total five-year requested support represents only a 17 percent increase from the prior funding period which is less than what would be expected from inflationary increases alone. This has been accomplished through utilizing non-CCSG sources of support for the OSUCCC. But it has been achieved primarily as an expression of the OSUCCC's effort to try to weigh its individual Center needs with the needs of all the other NCI approved cancer Centers and the contracted ability of the NCI budget to provide this support. The OSUCCC is proud of its past accomplishments and enthusiastically welcomes the challenges and opportunities described in this application for further expansion during the next five-year funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016058-24S2
Application #
6132835
Study Section
Cancer Center Support Review Committee (CCS)
Program Officer
Marino, Michael A
Project Start
1977-07-01
Project End
1999-11-30
Budget Start
1998-07-01
Budget End
1999-11-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
McKenna, Mary K; Noothi, Sunil K; Alhakeem, Sara S et al. (2018) Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia. Blood 131:2943-2954

Showing the most recent 10 out of 2602 publications